2025
Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Identifying the optimal post-surgical timing of molecular residual disease (MRD) detection in colorectal cancer (CRC) using an ultra-sensitive assay: Interim results from the VICTORI study. Journal Of Clinical Oncology 2025, 43: 275-275. DOI: 10.1200/jco.2025.43.4_suppl.275.Peer-Reviewed Original ResearchMolecular residual diseaseColorectal cancerCtDNA detectionDetection of molecular residual diseaseWeek 8Week 4Resectable colorectal cancerYear of surgeryTime of surgerySingle nucleotide variantsYear Follow-UpPost-surgical timesNeoadjuvant therapyResidual diseaseCurative intentMRD assaysResidual cancerClinical relapseDisease recurrenceCtDNA concentrationRecurrent cancerClinical outcomesCfDNA concentrationFollow-upRecurrence
2024
Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Solar Vasconcelos J, Titmuss E, Navarro F, Abbott C, Chia B, Topham J, Ladua G, Krishnan T, Hegebarth D, Lim H, Gill K, Gill S, Brown C, Ghuman A, Meneghetti A, Renouf D, Schaeffer D, Chen R, Boyle S, Loree J. Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay. Journal Of Clinical Oncology 2024, 42: e15625-e15625. DOI: 10.1200/jco.2024.42.16_suppl.e15625.Peer-Reviewed Original ResearchMolecular residual diseaseCirculating tumor DNARecurrence-free survivalColorectal cancerMRD assaysDetection of molecular residual diseaseLevels of circulating tumor DNAPoor recurrence-free survivalTreated with curative intentDetect circulating tumor DNAProspective cohort of patientsCurative interventionsCurative-intent treatmentCohort of patientsSingle nucleotide variantsStage I-IIISeparation of patientsMRD- patientsMRD testingNeoadjuvant treatmentResidual diseaseClinical recurrenceCurative intentRectal cancerTumor DNA
2023
Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update
Bhatia A, Burtness B. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update. Drugs 2023, 83: 217-248. PMID: 36645621, DOI: 10.1007/s40265-023-01835-2.Commentaries, Editorials and LettersConceptsNeck cancerRecurrent/metastatic settingImmune checkpoint inhibitor nivolumabNeck squamous cell carcinomaAge of immunotherapyLate stage HNSCCImmune checkpoint inhibitionPlatinum-containing chemotherapyFirst-line treatmentGrowth factor receptor overexpressionCheckpoint inhibitor nivolumabSquamous cell carcinomaEpidermal growth factor receptor (EGFR) overexpressionPathogenesis of HNSCCTreatment of patientsTreatment of HNSCCManagement of headMonoclonal antibody cetuximabCurative intentPalliative chemotherapyAdvanced diseaseInhibitor nivolumabLocoregional failureMetastatic settingMultimodality therapy
2022
Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts
Bewersdorf J, Rampal R. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts. Hematology 2022, 2022: 218-224. PMID: 36485103, PMCID: PMC9820986, DOI: 10.1182/hematology.2022000341.Peer-Reviewed Original ResearchConceptsMyeloproliferative neoplasmsBlast-phase MPNBlast-phase myeloproliferative neoplasmsAllogeneic hematopoietic cell transplantationBCR-ABL-negative myeloproliferative neoplasmsStages of clinical developmentMedian overall survivalHigh-risk molecular featuresHematopoietic cell transplantationCurative therapeutic modalityPrognosis of patientsAcute myeloid leukemiaMinority of patientsClinical trial enrollmentMPN-BPMyeloid blastsCurative intentHypomethylating agentsOverall survivalCell transplantationPeripheral bloodMyeloid leukemiaPalliative treatmentBone marrowClinical developmentDecision-making about gene therapy in transfusion dependent thalassemia
Quarmyne M, Ross D, Sinha C, Bakshi N, Boudreaux J, Krishnamurti L. Decision-making about gene therapy in transfusion dependent thalassemia. BMC Pediatrics 2022, 22: 536. PMID: 36085025, PMCID: PMC9461218, DOI: 10.1186/s12887-022-03598-3.Peer-Reviewed Original ResearchConceptsTransfusion-dependent thalassemiaPatient/family knowledgeDependent thalassemiaTransfusion independenceTreatment optionsStudy participantsGene therapyFamily knowledgeElimination of transfusionsFrequency of transfusionMorbidity/mortalityStem cell transplantationLong-term outcomesPreferred treatment modalityPromising treatment optionBackgroundHematopoietic stem cell transplantationPatients/familiesMethodsParents of childrenCurative intentTransfusion reductionHost diseaseDonor HSCTParents of childrenCell transplantationMean ageExercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline
Ligibel JA, Bohlke K, May AM, Clinton SK, Demark-Wahnefried W, Gilchrist SC, Irwin ML, Late M, Mansfield S, Marshall TF, Meyerhardt JA, Thomson CA, Wood WA, Alfano CM. Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. Journal Of Clinical Oncology 2022, 40: 2491-2507. PMID: 35576506, DOI: 10.1200/jco.22.00687.Peer-Reviewed Original ResearchConceptsWeight loss interventionCancer treatmentSystematic reviewNeutropenic dietPreoperative exerciseLoss interventionActive treatmentResistance exerciseLung cancerWeight managementActive cancer treatmentIntentional weight lossPatient-reported outcomesRisk of infectionQuality of lifeTypes of cancerCurative intentASCO guidelinesHospital stayPostoperative lengthTreatment toxicityOncology providersAdvanced cancerCochrane LibraryCardiorespiratory fitnessEvidence-Based Clinical Practice Guidelines for Extramammary Paget Disease
Kibbi N, Owen J, Worley B, Wang J, Harikumar V, Downing M, Aasi S, Aung P, Barker C, Bolotin D, Bordeaux J, Cartee T, Chandra S, Cho N, Choi J, Chung K, Cliby W, Dorigo O, Eisen D, Fujisawa Y, Golda N, Halfdanarson T, Iavazzo C, Jiang S, Kanitakis J, Khan A, Kim J, Kuzel T, Lawrence N, Leitao M, MacLean A, Maher I, Mittal B, Nehal K, Ozog D, Pettaway C, Ross J, Rossi A, Servaes S, Solomon M, Thomas V, Tolia M, Voelzke B, Waldman A, Wong M, Zhou Y, Arai N, Brackett A, Ibrahim S, Kang B, Poon E, Alam M. Evidence-Based Clinical Practice Guidelines for Extramammary Paget Disease. JAMA Oncology 2022, 8: 618-628. PMID: 35050310, DOI: 10.1001/jamaoncol.2021.7148.Peer-Reviewed Original ResearchConceptsExtramammary Paget's diseaseSecondary extramammary Paget's diseaseClinical practice guidelinesNonsurgical treatmentPaget's diseaseMalignant neoplasmsPractice guidelinesEvidence-based clinical practice guidelinesInvasive extramammary Paget's diseaseCarbon dioxide laser therapyClinical care recommendationsInternal malignant neoplasmsMultiple skin biopsiesDistant metastatic diseaseLymph node dissectionHigh-risk tumorsCare of adultsSuperior management approachCurative intentNode dissectionProspective registryMetastatic diseaseSentinel lymphSurgical resectionTumor characteristics
2021
A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study
Veludhandi A, Ross D, Sinha C, McCracken C, Bakshi N, Krishnamurti L. A Decision Support Tool for Allogeneic Hematopoietic Stem Cell Transplantation for Children With Sickle Cell Disease: Acceptability and Usability Study. JMIR Formative Research 2021, 5: e30093. PMID: 34709190, PMCID: PMC8587189, DOI: 10.2196/30093.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationSickle cell diseaseAllogeneic hematopoietic stem cell transplantationHealth care providersStem cell transplantationCare providersCell transplantationPatient consultsCell diseaseHCT comorbidity indexPhysician-patient collaborationOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesTransplant registry dataMost participantsHealth care settingsQuality of lifePatient-specific measuresCurative intentComorbidity indexHCT outcomesBlood transfusionRisk factorsPatient managementAssessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies
Katoch D, Krishnamurti L. Assessing Patient Preferences for Treatment Options for Pediatric Sickle Cell Disease: A Critical Review of Quantitative and Qualitative Studies. Patient Preference And Adherence 2021, 15: 2221-2229. PMID: 34629865, PMCID: PMC8493010, DOI: 10.2147/ppa.s264918.Peer-Reviewed Original ResearchSickle cell diseasePatient preferencesTreatment preferencesCell diseasePediatric sickle cell diseaseHematopoietic cell transplantPatients' treatment preferencesBurden of careQuality of lifeQualitative studyStandard gamble studyCurative intentRed blood cellsSupportive careSubstantial morbidityCell transplantImpaired qualityTreatment optionsIntravascular hemolysisPatient utilitiesPremature mortalityCaregiver perspectivesTreatment alternativesBlood cellsUtility studiesOutcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences
Marref I, Romain G, Jooste V, Vendrely V, Lopez A, Faivre J, Gerard J, Bouvier A, Lepage C. Outcomes of anus squamous cell carcinoma. Management of anus squamous cell carcinoma and recurrences. Digestive And Liver Disease 2021, 53: 1492-1498. PMID: 34193366, DOI: 10.1016/j.dld.2021.05.028.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaCell carcinomaAnal canalNet survivalBurgundy Digestive Cancer RegistryFive-year net survivalDigestive cancer registryCumulative recurrence ratePersistent active diseaseRisk of deathMultivariate survival analysisCumulative incidence functionCurative intentActive diseaseAbdominoperineal resectionAggressive managementCancer RegistryLocal inflammationRecurrence rateChemoradiotherapyCarcinomaRecurrenceRoutine practiceSurvival analysisRadiotherapyThymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: a European Society of Thoracic Surgeons Thymic Working Group Study
Guerrera F, Falcoz PE, Moser B, van Raemdonck D, Bille’ A, Toker A, Spaggiari L, Ampollini L, Filippini C, Thomas PA, Verdonck B, Mendogni P, Aigner C, Voltolini L, Novoa N, Patella M, Mantovani S, Bravio IG, Zisis C, Guirao A, Londero F, Congregado M, Rocco G, Du Pont B, Martucci N, Esch M, Brunelli A, Detterbeck FC, Venuta F, Weder W, Ruffini E, Centers T, Klepetko W, Olland A, Du Pont B, Nonaka D, Ozkan B, Iacono G, Braggio C, Filosso P, Brioude G, van Schil P, Nosotti M, Valdivia D, Bongiolatti S, Inci I, Dimitra R, Sànchez D, Grossi W, Moreno-Merino S, Teschner M. Thymomectomy plus total thymectomy versus simple thymomectomy for early-stage thymoma without myasthenia gravis: a European Society of Thoracic Surgeons Thymic Working Group Study. European Journal Of Cardio-Thoracic Surgery 2021, 60: 881-887. PMID: 34023891, PMCID: PMC10060729, DOI: 10.1093/ejcts/ezab224.Peer-Reviewed Original ResearchConceptsEarly-stage thymomaMyasthenia gravisTT groupST groupPropensity score-adjusted comparisonsNon-MG patientsPathological stage IPostoperative morbidity rateEuropean SocietyRate of complicationsCompleteness of resectionOverall survival rateLong-term outcomesProcedure of choiceMost relevant articlesOncological standpointCurative intentPostoperative complicationsPostoperative lengthTotal thymectomyOverall recurrenceThymic tumorsMorbidity rateSurgical approachThymus glandARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC).
Cecchini M, Krishnan K, Giafis N, Scott J, Quah C, Bendell J. ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer (mCRC). Journal Of Clinical Oncology 2021, 39: tps150-tps150. DOI: 10.1200/jco.2021.39.3_suppl.tps150.Peer-Reviewed Original ResearchMetastatic colorectal cancerStandard-of-careStandard-of-care armMFOLFOX-6Cohort BCohort AActivation of effector T cellsModified 5-fluorouracilTreated with FOLFOXDying cancer cellsDose-escalation studyEffector T cellsPhase Ib/II studyAdenosine receptor blockadeAdenosine receptor antagonistPhase 1b/2Escalation studyCurative intentReceptor blockadeOpen-labelImmunosuppressive adenosineCombination therapyPrimary endpointReceptor antagonistCohort C
2020
The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World
Thieblemont C, Chartier L, Dührsen U, Vitolo U, Barrington S, Vercellino L, Zaucha J, Carvalho I, da Silva Maria G, Decazes P, Viailly P, Tilly H, Berriolo-Riedinger A, Casasnovas R, Hüttmann A, Ilyas H, Mikhaeel G, Dunn J, Cottereau A, Schmitz C, Paulson J, Nielsen T, Meignan M. The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood 2020, 136: 30-31. DOI: 10.1182/blood-2020-136544.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaLarge B-cell lymphomaMetabolic tumor volumeProgression-free survivalB-cell lymphomaClinical trialsR-CHOPOverall survivalTumor volumeNewly diagnosed diffuse large B-cell lymphomaTotal metabolic tumor volumeStandard of careECOG PSCurative intentImmuno-chemotherapyPatientsMultiple centersEarly identificationCohortLymphomaTrialsSurvivalMultiple cohortsBaselineTMTVConsolidation Therapy in Primary Central Nervous System Lymphoma
Kim P, Omuro A. Consolidation Therapy in Primary Central Nervous System Lymphoma. Current Treatment Options In Oncology 2020, 21: 74. PMID: 32725379, DOI: 10.1007/s11864-020-00758-4.Peer-Reviewed Original ResearchConceptsWhole-brain radiation therapyCentral nervous system lymphomaLong-term remissionNervous system lymphomaConsolidation therapyInduction therapyPerformance statusTransplant candidatesSystem lymphomaOpinion statementPrimary central nervous system lymphomaPrimary central nervous system lymphomaAutologous stem cell transplantTransplant-related mortality riskAdequate organ functionFavorable performance statusInitial induction therapyECOG performance statusHigh-dose cytarabineHigh-dose methotrexateHigh-dose chemotherapyStem cell transplantEnd of inductionHigh response rateCurative intentMyeloablative regimenPotential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma
Haider SP, Zeevi T, Baumeister P, Reichel C, Sharaf K, Forghani R, Kann BH, Judson BL, Prasad ML, Burtness B, Mahajan A, Payabvash S. Potential Added Value of PET/CT Radiomics for Survival Prognostication beyond AJCC 8th Edition Staging in Oropharyngeal Squamous Cell Carcinoma. Cancers 2020, 12: 1778. PMID: 32635216, PMCID: PMC7407414, DOI: 10.3390/cancers12071778.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaProgression-free survivalPositron emission tomographySquamous cell carcinomaOverall survivalC-indexRisk stratificationCell carcinomaSurvival prognosticationHPV-negative oropharyngeal squamous cell carcinomaPre-treatment PET/CTMetastatic cervical lymph nodesBaseline positron emission tomographyBaseline distant metastasesCervical lymph nodesHuman papillomavirus (HPV) statusAmerican Joint CommitteeKaplan-Meier analysisPET/CT RadiomicsHarrell's C-indexAverage C-indexPET/CTRadiomics imaging featuresCurative intentDistant metastasisDefining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
Lievens Y, Guckenberger M, Gomez D, Hoyer M, Iyengar P, Kindts I, Méndez Romero A, Nevens D, Palma D, Park C, Ricardi U, Scorsetti M, Yu J, Woodward W. Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document. Radiotherapy And Oncology 2020, 148: 157-166. PMID: 32388150, DOI: 10.1016/j.radonc.2020.04.003.Peer-Reviewed Original ResearchConceptsMetastasis-directed radiotherapyDefinition of oligometastatic diseaseOligometastatic diseaseMetastatic sitesAbsence of clinical dataMetachronous oligometastatic diseaseRadiation oncology perspectiveDisease-free intervalSingle-centre seriesContext of radiotherapyPatient inclusion criteriaProgression-FreeMetastatic locationsCurative intentMetastatic lesionsOverall survivalPrimary tumorSystemic therapyOncological perspectiveQuality-of-lifeClinical dataRadiotherapyLocal controlConsensus documentInclusion criteriaSurgeon's Perspective to Local Therapy in Oligometastatic Cancer.
Boffa DJ. Surgeon's Perspective to Local Therapy in Oligometastatic Cancer. The Cancer Journal 2020, 26: 149-155. PMID: 32205540, DOI: 10.1097/ppo.0000000000000441.Peer-Reviewed Original Research
2019
Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse
Chemi F, Rothwell D, McGranahan N, Gulati S, Abbosh C, Pearce S, Zhou C, Wilson G, Jamal-Hanjani M, Birkbak N, Pierce J, Kim C, Ferdous S, Burt D, Slane-Tan D, Gomes F, Moore D, Shah R, Al Bakir M, Hiley C, Veeriah S, Summers Y, Crosbie P, Ward S, Mesquita B, Dynowski M, Biswas D, Tugwood J, Blackhall F, Miller C, Hackshaw A, Brady G, Swanton C, Dive C. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nature Medicine 2019, 25: 1534-1539. PMID: 31591595, PMCID: PMC6986897, DOI: 10.1038/s41591-019-0593-1.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerEarly-stage non-small-cell lung cancerDisease relapseGenomic profilingHigh risk of recurrenceDetection of circulating tumor cellsRisk of recurrenceTumor cell disseminationTime of surgeryPredictors of relapsePotential clinical utilityCurative intentPrimary tumorSurgical resectionTumor resectionTumor stagePredicting RelapseCell disseminationTumor cellsLung cancerMutational overlapRelapseMultivariate analysisSurgeryHigh riskRecurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms
Ohmori Y, Nomura T, Fukushima N, Takahashi F, Iwaya T, Koeda K, Nishizuka S, Consortium M. Recurrence risk evaluation in T1N1M0/T2N0M0/T3N0M0 gastric cancer with TP53 codon 72 polymorphisms. Journal Of Surgical Oncology 2019, 120: 1154-1161. PMID: 31578743, DOI: 10.1002/jso.25718.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCodonFemaleFollow-Up StudiesGastrectomyGenetic Predisposition to DiseaseGenotypeHumansIncidenceJapanMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPolymorphism, Single NucleotideRisk AssessmentStomach NeoplasmsSurvival RateTumor Suppressor Protein p53ConceptsRelapse-free survivalTP53 codon 72 polymorphismArg/ArgCodon 72 polymorphismGastric cancerOverall survivalHazard ratioHigh-risk patient groupsPostoperative adjuvant chemotherapyRecurrence risk evaluationArg/ProPro/Pro groupAdjuvant chemotherapyT3N0M0 patientsCurative intentStudy cohortPatient groupPro polymorphismEntire observation periodPolymorphism statusPRO groupPatientsArg/CancerPro/Communication Challenges: A Spotlight on New-Onset Refractory Status Epilepticus
Gofton TE, Wong N, Hirsch LJ, Hocker SE. Communication Challenges: A Spotlight on New-Onset Refractory Status Epilepticus. Mayo Clinic Proceedings 2019, 94: 857-863. PMID: 30935709, DOI: 10.1016/j.mayocp.2018.12.004.Peer-Reviewed Original ResearchConceptsNew-onset refractory status epilepticusRefractory status epilepticusClinical courseStatus epilepticusCritical care supportPalliative care servicesHealth care team membersUnpredictable clinical courseContinuity of careCare team membersCurative intentHealthy patientsDevastating conditionOngoing therapyResponsible physicianMultiple specialistsCare servicesCare supportMedical teamPatientsIndividual hospitalsYoung adultsEpilepticusEarly involvementCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply